Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 2, 2009 Brian Orelli	Squeezing Blood From a Half-Dollar Johnson & Johnson is investing $1 billion in Elan in exchange for an 18.4% stake in the company.
The Motley Fool December 28, 2010 Brian Orelli	No Guts, No Glory For better or worse, Elan gains full control of Alzheimer's drug ELND005.
The Motley Fool September 15, 2009 Brian Orelli	What's $115 Million Between Friends? Elan has to fix the mess it had gotten itself into with its multiple sclerosis drug Tysabri.
The Motley Fool October 28, 2011 Brian Orelli	Focus on Profits, Biotech Investors Elan is in the black and looking as healthy as ever.
Chemistry World August 14, 2012 Andrew Turley	Elan spins off drug discovery Irish drug maker Elan is to spin off its drug discovery activities as an independent company of 80 employees -- just under half the Elan workforce -- called Neotope Biosciences. The new company will focus on chronic degenerative diseases.
The Motley Fool September 30, 2009 Brian Orelli	More Questions Than Answers From Elan Things that make you go hmmm.
The Motley Fool August 4, 2010 Mac Greer	One Biotech Stock Ready to Rebound? One of our analysts gives you his thoughts on Elan.
The Motley Fool June 29, 2009 Brian Orelli	Another Day, Another Rumored Suitor The rumors surrounding Elan's strategic review and its suitors just keep getting weirder.
The Motley Fool August 17, 2010 Brian Orelli	Forget About This Drug Saving the Company Lilly's Alzheimer's drug fails hard.
The Motley Fool October 30, 2007 Brian Lawler	Lasting Longer Courtesy of Elan Elan announces that partner Johnson & Johnson has filed a marketing application for a once-a-month form of its anti-psychotic drug Invega. Investors, take note.
The Motley Fool February 11, 2010 Brian Orelli	Blockbuster in Hand, It's Time to Show a Profit Elan predicts an operating profit for the first time in nine years.
The Motley Fool May 22, 2007 Brian Lawler	Elan Plunges Ahead Shares of the drugmaker Elan have climbed more than 20% in the past two days after the company announced that it and partner Wyeth were moving their lead Alzheimer's disease treatment into phase 3 testing.
The Motley Fool February 9, 2011 Brian Orelli	Once a Decade Isn't Enough, Elan Elan posts its first operating profit in 10 years.
The Motley Fool August 10, 2010 Brian Orelli	Elan's Alternative to Strategic Alternatives Sometimes doing nothing is the best option.
The Motley Fool December 15, 2009 Brian Orelli	Forget the Higher Doses Elan has to drop the highest dose of an Alzheimer's drug. Again.
The Motley Fool June 18, 2007 Billy Fisher	Elan Elevates Its Game New drug prospects push the Dublin-based biotech's shares to a new 52-week high.
The Motley Fool October 22, 2009 Brian Orelli	Elan's Headed in the Right Direction Revenue up, costs down. It's a good direction for Elan to take, even if the company's final earnings number was slightly inflated.
The Motley Fool May 9, 2011 Brian Orelli	In Biotech, Two Platforms Are Better Than One Alkermes has swooped in and agreed to buy Elan Drug Technology for around $960 million.
The Motley Fool October 25, 2007 Brian Lawler	Tysabri, Elan, and a Prayer Investors seem impressed with Irish drugmaker Elan's third-quarter results; sales of their multiple sclerosis drug are picking up, but can they grow into the stock's valuation?
The Motley Fool December 19, 2011 Brian Orelli	Elan Turns It Around in 2011 Let's hope next year is as productive.
The Motley Fool June 18, 2008 Brian Lawler	Elan's and Wyeth's Data: Success or Failure? Elan and partner Wyeth released new mid-stage data for their potential blockbuster bapineuzumab (AAB-001) for Alzheimer's disease, but the results aren't conclusive.
The Motley Fool September 4, 2009 Brian Orelli	The Billion-Dollar Lovers' Quarrel Continues Elan had better bring candy and flowers to patch this up.
The Motley Fool August 1, 2008 Brian Lawler	Elan Becomes a Bad News Buy Shares of Elan are now undervalued, thanks to a big price drop following bad new about their multiple sclerosis drug.
The Motley Fool August 7, 2009 Brian Orelli	A Billion-Dollar Lovers' Quarrel It looks like the triangle between partners Elan and Biogen Idec and third-wheel Johnson & Johnson over the multiple sclerosis drug Tysabri is going to get settled in court.
The Motley Fool January 2, 2012 Anders Bylund	What Will Elan Do for an Encore? 2011 was a great year for the Irish biotech. Here's how that momentum carries through into 2012.
The Motley Fool July 31, 2008 Brian Lawler	Examining Elan's Ups and Downs Was the pharmaceutical's news about its potential Alzheimer's treatment as bad as investors treated it?
The Motley Fool June 1, 2009 Brian Orelli	Going Up for All the Wrong Reasons Bristol-Myers has been identified as Elan's mystery bidder. So what?
The Motley Fool October 31, 2006 Brian Lawler	A Foolish Trick: Elan Debt is coming due, and there's too much reliance on a single drug. Investors, beware.
The Motley Fool April 23, 2009 Brian Orelli	Elan's Strategic Uncertainty Elan has nothing new to report yet on the strategic review that Citigroup is preparing for them.
The Motley Fool April 21, 2011 Brian Orelli	Tysabri Means Everything to Biogen and Elan ... for Now It's rare to find a drug that affects two companies as much as Tysabri does Biogen Idec and Elan.
The Motley Fool July 30, 2007 Brian Lawler	The Good and Bad of Elan Investors, any bet on Elan is primarily a bet on the outcomes of Tysabri and AAB-001.
The Motley Fool August 10, 2005 Jack Uldrich	Does NanoCrystal Ball See All? There is promise in biotech Elan, but not for the reason you might think. Investors, take note.
The Motley Fool January 29, 2010 Brian Orelli	How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years.
The Motley Fool February 22, 2007 Brian Lawler	Too Much Aplomb From Elan Elan releases its 2006 financial results, and its future is not as rosy as seems. Investors, take note.
The Motley Fool March 15, 2007 Brian Lawler	Dueling Fools: Elan Bear How do you bring an Elan bear out of hibernation? Combine a crushing debt load, a huge cloud of uncertainty over its lead developmental drug program, and the launch of a new product that won't bring in enough revenue to sustain the current valuation, et voila! A bear is born.
The Motley Fool February 10, 2009 Brian Orelli	Elan Needs a Face-Lift Elan is in need of a serious makeover. The company has been beaten down severely, but there's still plenty of beauty in this pharma.
The Motley Fool April 3, 2009 Brian Orelli	Toning Down a Treatment Elan and Wyeth drop the highest dose of their Alzheimer's drug.
The Motley Fool February 8, 2005 Charly Travers	Investing in a Cure Drugs in the pipeline offer potential breakthroughs for Alzheimer's disease. Instead of investing in small biotechs that have a lot riding on a single Alzheimer's program, the best way to invest in the field is through a diversified company
The Motley Fool October 24, 2008 Brian Orelli	Elan's Approaching the Black Elan doesn't have positive cash flow yet, but it's getting closer, with revenue and expenses headed in the right direction.
The Motley Fool March 15, 2007 Anders Bylund	Dueling Fools: Elan Bull Granted, Elan isn't a stock for impatient investors, but those with patience will be rewarded in spades.
The Motley Fool January 8, 2004 Jeff Hwang	Elan's Happy Pill? Prialt's success injects positive vibe amid asset sales.
The Motley Fool August 27, 2009 Brian Orelli	Elan and J&J, Sitting in a Tree ... Johnson & Johnson dumps Alkermes for its new best bud in favor of Elan
The Motley Fool April 25, 2007 Brian Lawler	Where Is Elan Going? Drugmaker Elan announces first-quarter financial results. Investors, take note.
The Motley Fool October 5, 2006 Brian Lawler	Elan Extends Tysabri's Reach The MS-fighting drug gains approval in Canada. Next month, when Biogen and Elan report third-quarter results, investors will get a preliminary indication of how these sales of Tysabri are ramping up.
The Motley Fool September 14, 2009 Brian Orelli	The Clock Is Ticking for Elan Elan is getting closer to the Sept. 26 deadline to fix its contract with Johnson & Johnson. If it doesn't, Biogen Idec has the right to take full control of Elan's and Biogen's multiple-sclerosis drug, Tysabri.
The Motley Fool November 24, 2009 Brian Orelli	4 Platform Drugmakers to Invest In Elan ... Alkermes... Flamel Technologies... etc.
The Motley Fool May 27, 2011 Brian Orelli	What Kind of Phase 2 Drug Can You Get for $5 Million? Cell Therapeutics issues a press release saying the company has identified a potential acquisition opportunity that is a phase II drug candidate.
The Motley Fool March 17, 2008 Brian Orelli	Drugmakers That Make Rivals Green with Envy A look at some drugmakers with cash to spend: Pfizer...Wyeth... Novartis... Amylin Pharmaceuticals... Elan...Vertex Pharmaceuticals... Exelixis...
The Motley Fool April 5, 2005 Charly Travers	Has Elan Been KO'd? Tysabri is derailed but not necessarily off-track forever. The FDA needs to consider whether the real benefits to these patients outweigh the risk. But that's a highly uncertain outcome and a heck of decision on which to bet some investment dollars.
The Motley Fool December 31, 2011 Brian Orelli	3 More Stock-Moving Binary Events to Watch in 2012 There are a lot of drugs that will face binary events in 2012 -- here are three to watch.